BRIEF—Marinus sells priority review voucher for $110 million

Marinus Pharmaceuticals, a pharmaceutical company developing therapeutics to treat seizure disorders, has announced that it has closed on the sale of its Rare Pediatric Disease Priority Review Voucher for $110 million.

The $110 million adds to the $92.3 million in cash and cash equivalents reported as of June 30, 2022.

Marinus will use the proceeds for the commercial launch of Ztalmy (ganaxolone), a prescription medicine that is used to treat seizures associated with cyclin-dependent kinase-like 5 deficiency disorder, execution of its Phase III clinical programs in refractory status epilepticus and tuberous sclerosis complex, and other general expenditures.